Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell Announces Record Revenue of $3m for September Quarter
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell Appoints First Distributor for Remplirâ„¢ in US$75m Canadian Market
Orthocell has appointed its first Canadian distributor for Remplirâ„¢, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.Â
Global opportunity emerges as Remplirâ„¢ is used in nerve-sparing prostate cancer surgery
Orthocell has identified a promising new application for its flagship Remplirâ„¢ nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).
Remplirâ„¢ Real World Evidence study delivers compelling 81% success rate
Orthocell has today released interim results from a new Remplirâ„¢ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures.
Commercialisation of Remplirâ„¢ into US Market Continues to Build Momentum
Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplirâ„¢ in the US.
Orthocell Announces Changes to its Board of Directors
Orthocell has today announced some important changes to its Board of Directors.
First US Sales Revenue from Remplirâ„¢
Orthocell has today reached a critical milestone in the commercialisation of Remplirâ„¢ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.
OCC Quarterly Report | Quarter ended 30 June 2025
Orthocell has today released its Quarterly Report for the period ended 30 June 2025.
Orthocell Achieves a Record $2.73m in Revenue for June Quarter
Orthocell has announced record quarterly revenue of $2.73 million for the June quarter – our fifth consecutive quarter of record revenue growth.